ZoomInfo reports that 95% of enterprise AI projects fail to deliver ROI due to inadequate data infrastructure. Successful ...

Brokerages see the acquisition as aligned with Coforge's stated ambition to shift more deeply into higher-value, AI-driven ...

Patients in the ratutrelvir arm received ratutrelvir 600 mg orally once daily for 10 days, while patients in the comparator ...

Altimmune's pemvidutide shows strong Phase IIb results for MASH, promising Phase III prospects. Read here for more analysis ...

As AI-driven power demand accelerates, geothermal energy is quietly moving from conceptual promise toward early execution: ...

Networking can be as simple as publishing your own work, commenting on other’s work or initiating conversations with ...

Jefferies analyst Julien Dumoulin-Smith upgraded the stock to Buy, citing improved visibility across gas power and ...

With a late-stage miss reported for its prospective social anxiety disorder (SAD) treatment fasedienol, Vistagen’s chances at ...

December 26, 2025 A newly released clinical review is drawing attention within medical and regulatory communities by consolidating available evidence on the side-effect profile of a widely prescribed ...

Traders are positioning for downside risks, with a significant build-up of put options indicating expectations of a dip below ...

Argenx SE has discontinued the phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate to severe thyroid eye disease (TED ...